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D upuytren disease (DD) is a slowly progressing fibroproliferative disorder of the palmar fasci-ae. Characteristic thickening of the skin, nod-
ules, and cords causes a progressive extension deficit 
resulting in impaired hand function. DD is very com-
mon among Caucasians and their Northern European 
descendants.1
Traditionally, the preferred method of treatment has 
been surgical procedures such as percutaneous needle fas-
ciectomy, limited fasciectomy, or dermofasciectomy with 
or without skin grafting. Surgical procedures are associ-
ated with intraoperative risk of damage to nerves, arteries, 
and tendons.2 Postoperative risks include infection, hema-
tomas, and impaired wound healing. With multiple surgi-
cal interventions in the same area, the risks increase, as do 
the demands on the surgeon’s skills and patience.
A nonsurgical treatment with an injection of collage-
nase clostridium histolyticum (CCH) has been offered in 
recent years. This enzyme degrades and weakens a part of 
the cord into which it has been injected, and after injec-
tion of local anesthetics and manipulation, the extension 
deficit is released or diminished.
Since the introduction of CCH to the Danish market 
in 2011, several studies describing the effect have been 
published.3,4 The anatomical differences in contractures 
affecting the proximal interphalangeal (PIP) joint and the 
metacarpophalangeal (MP) joint have been suggested as a 
cause of different treatment potential.5
The aim of this study was to evaluate the difference in 
efficiency and recurrence when treating MP and PIP joints 
with CCH in patients with primary DD.
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Background: Dupuytren disease (DD) is a fibroproliferative disorder of the pal-
mar fasciae causing extension deficit and impaired hand function. Treatment with 
injection of collagenase clostridium histolyticum (CCH) is a nonsurgical treat-
ment method. The aim of this study was to evaluate the difference in efficiency 
and recurrence at 12-month follow-up when treating metacarpophalangeal (MP) 
and proximal interphalangeal (PIP) joints with CCH. None of the patients had 
received previous treatments of their condition.
Methods: This study is a prospective study of a consecutive series of patients with 
DD presenting with an extension deficit greater than 20° affecting the MP or PIP 
joint.
Results: We found a mean reduction in extension deficit of 47° (91%) for MP 
joints and 47° (76%) for PIP joints. Full correction (max 5° deficit) was achieved 
in 76% of MP and 28% of PIP joints. Skin rupture was seen in 34% of treatments. 
The 1-year relapse rate was 15% for MP and 67% for PIP joints. The reduction in 
quickDASH score was only statistically significant for MP joints at 1 year. Eighty-one 
percent of all patients reported being satisfied or very satisfied. No major adverse 
events were recorded.
Conclusion: Excellent results can be achieved in the treatment of MP-joint con-
tractures, whereas the success rate is significantly lower and recurrence rate is 
greater for PIP joints. (Plast Reconstr Surg Glob Open 2017;5:e1275; doi: 10.1097/
GOX.0000000000001275; Published online 25 April 2017.)
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METHODS
Study Design and Patient Population
A prospective cohort study was conducted on a con-
secutive series of patients with primary DD treated at 
Odense University Hospital from July 2011 to the end 
of December 2013. The patients received no previous 
surgical treatment or CCH injections and were thus 
classified as primary DD patients. All research was car-
ried out in compliance with the Declaration of Helsinki. 
The study was approved by the Danish Data Protection 
Agency and the regional ethics committee. All patients 
agreed to participate in the study, provided written in-
formed consent, and were free to be excluded from the 
study at any time.
All patients presented with >20° extension deficit 
over one joint and a palpable cord (see Table 1). The 
primary endpoint was a reduction in extension deficit to 
0° to 5° of full extension for a joint. PIP- and MP-joint 
extension deficits were evaluated separately. Second-
ary endpoints included patient-reported hand function 
using the Disabilities of the Arm, Shoulder and Hand 
(quickDASH) questionnaire, patient satisfaction, and 
recurrence of extension deficit and occurrence of ad-
verse events after a 12-month follow-up period.
Treatment
Three experienced hand surgeons performed all treat-
ments in the same clinical setting. If the patient received 
anticoagulating therapy, the need for bridging with hepa-
rin before injection was assessed before treatment. Injec-
tions were given to correct flexion deformities one joint at 
a time. For patients with both MP and PIP contractures, 2 
treatments were given with an interval of at least 30 days 
between injections. MP joints were treated before PIP 
joints, and patients were involved in prioritizing the order 
of fingers treated. Injection and manipulation technique 
was not altered during the study. The examiner was the 
treating surgeon at all times.
Day 1
The quickDASH score was recorded, and the passive 
extension deficits of the MP, PIP, and distal interphalan-
geal joints were measured using a goniometer. Extension 
deficits were measured relative to neutral in all joints. All 
surgeons were instructed in the use of CCH, and injections 
were carried out according to the product label guidelines 
and as described by Hentz.6
After injection, a soft dressing was applied.
Day 2
Major and minor adverse events and the need for pain 
medication were assessed. If no spontaneous rupture had 
occurred, 5 to 10 ml of lidocaine (either 10 or 20 mg/
ml) was injected before manipulation. Residual exten-
sion deficit was recorded using a goniometer, the occur-
rence of skin tears was noted, and the need for additional 
follow-up assessed. A nonadhesive dressing was applied, 
and patients were educated in wound care. All patients 
were given a removable forearm-based splint to be worn 
at night for 4 months. The splint kept the treated finger 
in extension. Patients received instruction on performing 
finger exercises at home.
One-year Follow-up
At least 12 months after treatment, quickDASH scores, 
extension deficits, complications, and recurrences were 
recorded by the treating surgeon. Patient satisfaction at 1 
year was recorded.
Statistical Methods and Definitions
Data were entered under quality-assured proce-
dures using the EpiData Software (www.epidata.dk, 
EpiData Classic, Odense, Denmark) and were analyzed 
using Stata (www.stata.com—v14, StataCorp LLC, Col-
lege Station, Tex.). All differences were calculated as 
intraindividual and joint-specific excluding the quick-
DASH scores, which were recorded at patient level. All 
confidence intervals (CIs) were 95% and calculated 
according to type of estimate (proportion, means). 
Intraindividual changes over time in goniometric mea-
surements were tested with a paired t test, crosstabu-
lations with chi-square. A 0°–5° extension deficit was 
defined as successful treatment result in accordance 
with previous studies,7–9 and recurrence defined as more 
than 20° of relapse in extension deficit in the treated 
joint.10 Patient satisfaction was measured on a 5-point 
ordinal scale (“very satisfied,” “quite satisfied,” “neither 
satisfied/nor dissatisfied,” “quite dissatisfied,” “very dis-
satisfied”). The patient’s specific reason for satisfaction 
or dissatisfaction was not noted.
Material
During the 30-month inclusion period, 340 patients 
with Dupuytrens Contracture were referred to the depart-
ment. Of the patients treated, 88% received CCH injec-
tion. A total of 235 CCH treatments were given to 212 
individuals (195 male and 40 female treatments, see Fig. 1 
and Table 2).
The majority of the patients received 1 treatment 
(90%). Eighteen patients received 2 treatments (8%), 
and 4 patients received 3 treatments (2%). A total of 
208 patients were seen at an average of 15 months of 
follow-up.
A total of 14 patients were listed as dropouts. No re-
lation to joints, finger, or other patient-related factors 
could be identified. One patient declined manipulation 
and administration of local anesthetics and asked to be 
excluded on day 2. One died from circumstances unrelat-
ed to DD and CCH treatment. Thumbs were excluded as 
Table 1.  Inclusion and Exclusion Criteria
Inclusion Criteria Exclusion Criteria
MP- or PIP-joint  
contracture >20°
<18 y
Primary Dupuytren  
contracture
Prior resection of axillary lymph 
nodes
Single palpable cord Wounds or skin lesion on the hand
 Investigational drugs within 30 d
 Tetracycline derivatives within 14 d
 Allergy to collagenase
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they are considered anatomically incomparable with the 
ulnar digits (n = 3). Seven patients (2.9%) were excluded 
from the 1-year relapse statistics because they had under-
gone surgery within 1 year of the primary treatment. In-
dication for surgery was absence of cord rupture or the 
patient being unsatisfied with an only partial release of 
the extension deficit.
An attempt was made to contact patients lost to 
follow-up. Reasons for not participating were either 
geographical or caused by severe, unrelated illness. Ac-
cording to the national electronic patient files, none 
of these 13 patients received surgical treatment at the 
1-year follow-up.
RESULTS
Spontaneous rupture of the cord was recorded in 5% 
of treatments. For all treated MP joints, the initial ex-
tension deficit was 51° (95% CI: 48–54), and the mean 
improvement in the extension deficit was 47°, correspond-
ing to a 91% reduction in the extension deficit.
For all treated PIP joints, the initial extension deficit 
was 62° (95% CI: 57–66), and the mean improvement in 
the extension deficit was 47°, corresponding to a 76% re-
duction in the extension deficit (see Fig. 2).
With a successful result defined as an extension defi-
cit of 5° or less, we found an average success rate of 76% 
(95% CI: 68–82) for MP joints and 28% (95% CI: 17–40) 
for PIP joints. The success rate with CIs for each joint can 
be seen in Figures 3, 4.
As a result of manipulation, 30% (n = 70) developed a 
skin tear, and of these treatments, 76% (n = 53) had a need 
for additional visits to the outpatient clinic. No infections 
were recorded. All skin tears healed within a few weeks.
Of all 208 treatments, 50% of patients reported the 
need to use over-the-counter medication for pain after the 
injection (acetaminophen or ibuprofen).
Follow-up at 12 Months
For MP joints, the mean relapse in the extension defi-
cit was 4°, which was not statistically significant. For PIP 
joints, a significant relapse in extension deficit was 23°, 
which corresponds to a relapse of 49%. Recurrence (>20°) 
was seen in 67% (n = 12) of successfully corrected PIP 
joints (n = 18) and 15% (n = 19) of MP joints (n = 123) at 
>12 months of follow-up (see Table 3). The mean quick-
DASH score for MP joints was reduced from 17 (95% CI: 
Fig. 1. Flowchart accounting for all patients referred to our department with DD. gP; general practitioner.
Table 2.  Sex, Age, and Side Treated (n = 235 Treatments)
Sex (n) Male, 195 (83%); female, 40 (17%)
Mean age (y) 66 (interquartile range, 60–73)
Affected hands left/right 50%/50%
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14–19) to 7 (95% CI: 5–9). No significant improvement 
in the quickDASH score was found for PIP joints. The 
majority (86%) of patients reported being either satisfied 
or very satisfied with the treatment at the 1-year follow-up 
for MP joints and 69% for PIP joint contractures. Minor 
adverse events were all mild and spontaneously resolved 
(Table 4). No major adverse events have been recorded 
to date (Table 5). To the authors’ knowledge, no patients 
have experienced severe adverse events to date.
DISCUSSION
The study demonstrates a large difference in treatment 
success and recurrence when treating MP joints and PIP 
joints. Treatment success was especially difficult to achieve 
in PIP joints, and relapse was more frequent compared 
with MP joints. Mild adverse events are frequent but ac-
ceptable. Patient satisfaction is high.
The quickDASH questionnaire has limitations when 
evaluating patients with DD,11 and we were only able to 
Fig. 2. improvement in passive extension deficit from day 1 to immediately after treat-
ment and after 1 year of follow-up (mean extension deficits with 95% cis). Day 1, ex-
tension deficit, before treatment; day 2, extension deficit, immediately after manipula-
tion; 12m, extension deficit, at 1-year follow-up; MP, dif, mean, difference in extension 
deficit from day 2 to 1-year follow-up; PiP, dif, mean difference in extension deficit 
from day 2 to 1-year follow-up.
Fig. 3. Proportion of MP joints that reached clinical success, defined as a less than or 
equal to 5° passive extension deficit after manipulation with 95% cis.
Fig. 4. Proportion of PiP joints that reached clinical success, defined as a less than 5° 
passive extension deficit after manipulation with 95% cis.
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show a significant improvement for treated MP joints. 
There is currently no alternative validated tool in Danish.
The study reflects the situation in clinical practice, 
with an emphasis on patient choice in regard to priori-
tizing treatment and in the use of patient-reported out-
come measures to evaluate the efficiency of treatment. Of 
all patients treated (CCH or surgery), 88% were treated 
with CCH, including patients who could not be expected 
achieve a perfect result, because of a severe initial exten-
sion deficit. This may in part explain the high incidence of 
skin rupture. Another reason may be that we do not con-
sider skin rupture problematic and do not seek to avoid it.
As a potential bias to our study, 7 patients with com-
plete treatment failure were excluded, as described in the 
study design section. Including these patients in the sta-
tistics would have resulted in a 2% decrease in the over-
all success rate. Although none of the 13 patients lost to 
follow-up had undergone surgery according to the na-
tional patient files, this does not exclude the possibility of 
recurrence.
Our department was the first in the country to offer 
collagenase treatment, and therefore, patients from all 
over the country were initially treated. This is reflected in 
the number of patients lost to follow-up (n = 13). In par-
ticular, it was difficult for elderly patients with comorbidi-
ties to travel far distances for their follow-up visits.
Initially, patients had high expectations for the col-
lagenase treatment and were at times discouraged when 
a residual extension deficit was present after treatment. 
As the study progressed, the treating surgeons became in-
creasingly aware of the treatment effect and patient infor-
mation and satisfaction improved accordingly.
Treatment failure in patients with long-lasting, severe 
contracture, especially of the PIP joints, can be due to 
tight collateral ligaments, volar plates, and/or joint cap-
sule. It is well known from open surgical procedures that 
even removal of all Dupuytren’s tissue may not lead to any 
reduction in extension deficit in the PIP joint. The reason 
for this being that the contracture in chronic cases primar-
ily lies in anatomical joint structures such as the accessory 
collateral ligaments and the volar plate.5
Absence of cord rupture can be due to incorrect in-
jection technique, the injection of air or of inactive sub-
stances, or patient-related factors. Caution must be taken 
during the injection process and when handling the CCH.
Since the early landmark studies, several studies have 
proven CCH to be effective in the treatment of DD. Sever-
al of these previous studies addressed the efficacy of CCH 
for the MP and PIP joints and found results comparable to 
ours. Studying a total of 1080 treated joints and using the 
same criteria for success and relapse, Peimer et al.12 found 
that the majority of treated MP joints (70%) were success-
fully treated, whereas PIP joints (40%) were less prone to 
reach full extension. For successfully treated joints, a 27% 
relapse for MP joints and 56% relapse for PIP joints at 3 
years of follow-up were reported. This multicenter study 
included a very large number of contributors and is not 
directly comparable to our single-center study, and yet it 
supports our finding that the success rate, when treating 
MP joints, is approximately 3 out of 4. The fact that our 
success rate when treating PIP joint is only 28% compared 
to Peimer’s 40% may be due to differences in patient se-
lection. The fact that reported relapse rates for MP joints 
were much greater suggests that studies examining relapse 
frequencies must be long term.
Peimer et al.13 have published a series of 950 patients. 
Compared with our reported 1-year relapse rate of 15%, 
for MP joints, this study found a 39% 5-year relapse rate 
for MP joints, suggesting that a good initial result does 
not guarantee that relapse will not occur. Additionally, this 
study found a 66% 5-year relapse rate in PIP joints, which 
Table 3.  Results of Treatment Immediately after Manipulation and at 1-year Follow-up for Individual Joints
 Success (N) Success* % (95% CI)
1-y Relapse among Patients 
Treated Successfully (N)
Relapse % among the 
Successful Treatments†
MP2 1/1 ‡ 0/1 0
MP3 9/13 69 (39–91) 1/9 11
MP4 60/70 86 (75–93) 8/58 14
MP5 58/86 67 (56–77) 10/55 18
MP all 128/170 76 (68–82) 19/123 15
PIP2 1/3 ‡ 1/1 100
PIP3 None treated - — —
PIP4 6/16 38 (15–65) 3/6 50
PIP5 11/46 24 (13–39) 8/11 73
PIP all 18/65 28 (17–40) 12/18 67
Numbers in bracket represent 95% CIs.
*Success defined as extension deficit <6° immediately after treatment.
†Relapse defined as at least 20° loss of passive extension from the primary result.
‡Excluded from analysis because of small numbers.
Table 4.  Minor Adverse Events
Edema of finger 84%




Injection site pain 47%
Skin rupture 34%
Table 5.  Major Adverse Events
Tendon rupture 0%
Nerve damage 0%
Complex regional pain syndrome 0%
Infection 0%
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is comparable to our 67% relapse rate at 1 year. This may 
suggest that PIP joints relapse faster than MP joints.
Manning et al.14 treated 45 patients with a total of 50 
injections and observed a 90% reduction in extension 
deficit for MP joints, which is very similar to our result of 
93%. Witthaut et al.9 also reported similar results treating 
879 joints and had a success rate of 70% for MP joints and 
37% for PIP joints.
Other studies have addressed adverse events and have 
reported high incidences of mild adverse events. A study 
pooling 11 trials found a 0.3% rate of tendon injury, a 16% 
rate of skin rupture, a 77% rate of hematomas, a 0.1% 
rate of complex regional pain syndrome, and no nerve 
or vascular injury.15 In line with these results, we found a 
very low incidence of major adverse events (Tables 4, 5), 
although minor adverse events, including skin rupture, 
were common.
CCH is effective in reducing extension deficit caused 
by DD with acceptable adverse events. Patients should be 
properly counseled about the potential benefits and risks 
of treatment, and that for patients with extensive contrac-
tures of multiple joints, surgery may be a better choice.
A review by Eaton16 suggested that the recurrence of 
DD with CCH may be comparable to that with needle fas-
ciotomy after 2 years of follow-up and greater than that 
with limited fasciectomy after 5 years of follow-up. Ran-
domized controlled trials comparing CCH with needle fas-
ciotomy and open fasciectomy will prove to be a great help 
in the future selection of treatment for DD.
Karina Liv Hansen, MD
Department of Orthopaedic Surgery and Traumatology
Odense University Hospital
Søndre Boulevard 29
DK-5000 Odense C, Denmark
E-mail: karina.liv.hansen@rsyd.dk
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